CoChat

The role of GIP in α-cells and glucagon secretion

Open access
El, Kimberley, Campbell, Jonathan E. · 2020 · Peptides
Cited by 96

The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.

Abstract

Glucose-dependent insulinotropic polypeptide (GIP) is an intestinally derived peptide that is secreted in response to feeding. The GIP receptor (GIPR) is expressed in many cell types involved in the regulation of metabolism, including α- and β-cells. Glucagon and insulin exert tremendous control over glucose metabolism. Thus, GIP action in islets strongly dictates metabolic control in the postprandial state. Loss of GIPR activity in β-cells is a characteristic of type 2 diabetes (T2D) which associates with reduced postprandial insulin secretion and hyperglycemia. Less is known about GIPR activity in α-cells or the control of glucagon secretion. GIP stimulates glucagon secretion in a glucose-dependent manner in healthy people, with enhanced activity at lower glycemia. However, GIP stimulates glucagon secretion even at hyperglycemia in people with T2D, suggesting that inappropriate GIPR activity in α-cells contributes to the pathogenesis of T2D. Here, we review the literature describing GIP action and GIPR activity in the α-cell, detailing the basic science that has shaped the view of how GIP regulates glucagon secretion. We also contrast the effects of GIP on glucagon secretion in healthy and T2D people. Finally, we contextualize these observations in light of recent work that redefines the role of glucagon in glucose homeostasis, suggesting that hyperglucagonemia per se does not drive hyperglycemia. As new medications for T2D that incorporate GIPR activity are being developed, it is clear that a better understanding of GIPR activity beyond the β-cell is necessary. This work highlights the importance of focusing on the GIPR in α-cells.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.peptides.2019.170213

Cites

29 of 29 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 29 references

Research works printed but not linked: 53

  1. Kreymann, 1987, Glucagon-like peptide-1 7-36: a physiological incretin in man, Lancet, 2, 1300, 10.1016/S0140-6736(87)91194-9 · DOI · Paper page
  2. Campbell, 2015, Islet alpha cells and glucagon--critical regulators of energy homeostasis, Nat. Rev. Endocrinol., 11, 329, 10.1038/nrendo.2015.51 · DOI · Paper page
  3. Holst, 2011, Loss of incretin effect is a specific, important, and early characteristic of type 2 diabetes, Diabetes Care, 34, S251, 10.2337/dc11-s227 · DOI · Paper page
  4. Zhou, 2007, Ubiquitination is involved in glucose-mediated downregulation of GIP receptors in islets, Am. J. Physiol. Endocrinol. Metab., 293, E538, 10.1152/ajpendo.00070.2007 · DOI · Paper page
  5. Xu, 2007, Downregulation of GLP-1 and GIP receptor expression by hyperglycemia: possible contribution to impaired incretin effects in diabetes, Diabetes, 56, 1551, 10.2337/db06-1033 · DOI · Paper page
  6. Lefebvre, 2015, Inhibiting or antagonizing glucagon: making progress in diabetes care, Diabetes Obes. Metab., 17, 720, 10.1111/dom.12480 · DOI · Paper page
  7. Johnson, 1982, Hyperglycemia of diabetic rats decreased by a glucagon receptor antagonist, Science, 215, 1115, 10.1126/science.6278587 · DOI · Paper page
  8. Chepurny, 2019, Correction: nonconventional glucagon and GLP-1 receptor agonist and antagonist interplay at the GLP-1 receptor revealed in high-throughput FRET assays for cAMP, J. Biol. Chem., 294, 8714, 10.1074/jbc.AAC119.009193 · DOI
  9. Capozzi, 2019, Beta Cell tone is defined by proglucagon peptides through cAMP signaling, JCI Insight, 4, 10.1172/jci.insight.126742 · DOI · Paper page
  10. Svendsen, 2018, Insulin secretion depends on intra-islet glucagon signaling, Cell Rep., 25, 1127, 10.1016/j.celrep.2018.10.018 · DOI · Paper page
  11. Rodriguez-Diaz, 2018, Paracrine interactions within the pancreatic islet determine the glycemic set point, Cell Metab., 27, 549, 10.1016/j.cmet.2018.01.015 · DOI · Paper page
  12. Zhu, 2019, Intra-islet glucagon signaling is critical for maintaining glucose homeostasis, JCI Insight, 5
  13. Capozzi, 2019, Glucagon lowers glycemia when beta-cells are active, JCI Insight, 5
  14. Chambers, 2017, The role of pancreatic preproglucagon in glucose homeostasis in mice, Cell Metab., 25, 927, 10.1016/j.cmet.2017.02.008 · DOI · Paper page
  15. Chia, 2009, Exogenous glucose-dependent insulinotropic polypeptide worsens post prandial hyperglycemia in type 2 diabetes, Diabetes, 58, 1342, 10.2337/db08-0958 · DOI · Paper page
  16. Xin, 2016, Use of the Fluidigm C1 platform for RNA sequencing of single mouse pancreatic islet cells, Proc. Natl. Acad. Sci. U. S. A., 113, 3293, 10.1073/pnas.1602306113 · DOI · Paper page
  17. Ding, 1997, Glucagon-like peptide I and glucose-dependent insulinotropic polypeptide stimulate Ca2+-induced secretion in rat alpha-cells by a protein kinase A-mediated mechanism, Diabetes, 46, 792, 10.2337/diab.46.5.792 · DOI · Paper page
  18. Hughes, 2018, Regulation of islet glucagon secretion: beyond calcium, Diabetes Obes. Metab., 20, 127, 10.1111/dom.13381 · DOI · Paper page
  19. Meier, 2007, Suppression of glucagon secretion is lower after oral glucose administration than during intravenous glucose administration in human subjects, Diabetologia, 50, 806, 10.1007/s00125-007-0598-z · DOI
  20. de Heer, 2008, Glucagon-like peptide-1, but not glucose-dependent insulinotropic peptide, inhibits glucagon secretion via somatostatin (receptor subtype 2) in the perfused rat pancreas, Diabetologia, 51, 2263, 10.1007/s00125-008-1149-y · DOI · Paper page
  21. Sparre-Ulrich, 2017, GIP(3-30)NH2 is a potent competitive antagonist of the GIP receptor and effectively inhibits GIP-mediated insulin, glucagon, and somatostatin release, Biochem. Pharmacol., 131, 78, 10.1016/j.bcp.2017.02.012 · DOI · Paper page
  22. Opara, 1991, Influence of gastric inhibitory polypeptide (GIP) and glucose on the regulation of glucagon secretion by pancreatic alpha cells, Regul. Pept., 32, 65, 10.1016/0167-0115(91)90035-F · DOI
  23. Tengholm, 2012, Cyclic AMP dynamics in the pancreatic beta-cell, Ups. J. Med. Sci., 117, 355, 10.3109/03009734.2012.724732 · DOI
  24. Franklin, 2005, Beta-cell secretory products activate alpha-cell ATP-dependent potassium channels to inhibit glucagon release, Diabetes, 54, 1808, 10.2337/diabetes.54.6.1808 · DOI · Paper page
  25. Ishihara, 2003, Islet beta-cell secretion determines glucagon release from neighbouring alpha-cells, Nat. Cell Biol., 5, 330, 10.1038/ncb951 · DOI · Paper page
  26. Elliott, 2015, Somatostatin and insulin mediate glucose-inhibited glucagon secretion in the pancreatic alpha-cell by lowering cAMP, Am. J. Physiol. Endocrinol. Metab., 308, E130, 10.1152/ajpendo.00344.2014 · DOI · Paper page
  27. Schuit, 1989, Sensitivity of rat pancreatic A and B cells to somatostatin, Diabetologia, 32, 207, 10.1007/BF00265096 · DOI
  28. Szecowka, 1982, Effect of GIP on the secretion of insulin and somatostatin and the accumulation of cyclic AMP in vitro in the rat, Acta Endocrinol (Copenh), 99, 416
  29. Moss, 2012, Somatostatin receptor 5 and cannabinoid receptor 1 activation inhibit secretion of glucose-dependent insulinotropic polypeptide from intestinal K cells in rodents, Diabetologia, 55, 3094, 10.1007/s00125-012-2663-5 · DOI · Paper page
  30. Rutter, 2009, Regulating glucagon secretion: somatostatin in the spotlight, Diabetes, 58, 299, 10.2337/db08-1534 · DOI
  31. Chia, 2014, GIP contributes to islet trihormonal abnormalities in type 2 diabetes, J. Clin. Endocrinol. Metab., 99, 2477, 10.1210/jc.2013-3994 · DOI · Paper page
  32. Lund, 2011, The separate and combined impact of the intestinal hormones, GIP, GLP-1, and GLP-2, on glucagon secretion in type 2 diabetes, Am. J. Physiol. Endocrinol. Metab., 300, E1038, 10.1152/ajpendo.00665.2010 · DOI · Paper page
  33. Christensen, 2014, Glucose-dependent insulinotropic polypeptide: blood glucose stabilizing effects in patients with type 2 diabetes, J. Clin. Endocrinol. Metab., 99, E418, 10.1210/jc.2013-3644 · DOI · Paper page
  34. Finan, 2019, Repositioning glucagon action in the physiology and pharmacology of diabetes, Diabetes
  35. Christensen, 2015, Glucose-dependent insulinotropic polypeptide augments glucagon responses to hypoglycemia in type 1 diabetes, Diabetes, 64, 72, 10.2337/db14-0440 · DOI · Paper page
  36. Christensen, 2010, Glucagon-like peptide-2, but not glucose-dependent insulinotropic polypeptide, stimulates glucagon release in patients with type 1 diabetes, Regul. Pept., 163, 96, 10.1016/j.regpep.2010.05.004 · DOI
  37. Stehouwer, 2018, Microvascular dysfunction and hyperglycemia: a vicious cycle with widespread consequences, Diabetes, 67, 1729, 10.2337/dbi17-0044 · DOI · Paper page
  38. Saxena, 2010, Genetic variation in GIPR influences the glucose and insulin responses to an oral glucose challenge, Nat. Genet., 42, 142, 10.1038/ng.521 · DOI · Paper page
  39. Speliotes, 2010, Association analyses of 249,796 individuals reveal 18 new loci associated with body mass index, Nat. Genet., 42, 937, 10.1038/ng.686 · DOI · Paper page
  40. Lyssenko, 2011, Pleiotropic effects of GIP on islet function involve osteopontin, Diabetes, 60, 2424, 10.2337/db10-1532 · DOI · Paper page
  41. Arora, 2018, Association between genetic risk variants and glucose intolerance during pregnancy in north Indian women, BMC Med. Genomics, 11, 64, 10.1186/s12920-018-0380-8 · DOI
  42. Han, 2016, IGF2BP2 rs11705701 polymorphisms are associated with prediabetes in a Chinese population: a population-based case-control study, Exp. Ther. Med., 12, 1849, 10.3892/etm.2016.3554 · DOI
  43. Javorsky, 2016, A missense variant in GLP1R gene is associated with the glycaemic response to treatment with gliptins, Diabetes Obes. Metab., 18, 941, 10.1111/dom.12682 · DOI
  44. Berglund, 2016, Glucose-dependent insulinotropic polypeptide stimulates osteopontin expression in the vasculature via Endothelin-1 and CREB, Diabetes, 65, 239, 10.2337/db15-0122 · DOI · Paper page
  45. Garg, 2016, Glucose-dependent insulinotropic polypeptide (GIP) and GIP receptor (GIPR) genes: an association analysis of polymorphisms and bone in young and elderly women, Bone Rep., 4, 23, 10.1016/j.bonr.2015.12.001 · DOI
  46. Ono, 2015, GIPR gene polymorphism and weight gain in patients with schizophrenia treated with olanzapine, J. Neuropsychiatry Clin. Neurosci., 27, 162, 10.1176/appi.neuropsych.13120389 · DOI
  47. Ahlqvist, 2013, Link between GIP and osteopontin in adipose tissue and insulin resistance, Diabetes, 62, 2088, 10.2337/db12-0976 · DOI · Paper page
  48. Sonestedt, 2012, Genetic variation in the glucose-dependent insulinotropic polypeptide receptor modifies the association between carbohydrate and fat intake and risk of type 2 diabetes in the Malmo Diet and Cancer cohort, J. Clin. Endocrinol. Metab., 97, E810, 10.1210/jc.2011-2444 · DOI · Paper page
  49. Ono, 2012, Association between the GIPR gene and the insulin level after glucose loading in schizophrenia patients treated with olanzapine, Pharmacogenom. J., 12, 507, 10.1038/tpj.2011.28 · DOI
  50. Joo, 2017, Inhibition of gastric inhibitory polypeptide receptor signaling in adipose tissue reduces insulin resistance and hepatic steatosis in high-fat diet-fed mice, Diabetes, 66, 868, 10.2337/db16-0758 · DOI · Paper page
  51. Beaudry, 2019, Physiological roles of the GIP receptor in murine brown adipose tissue, Mol. Metab., 10.1016/j.molmet.2019.08.006 · DOI · Paper page
  52. Ussher, 2018, Inactivation of the glucose-dependent insulinotropic polypeptide receptor improves outcomes following experimental myocardial infarction, Cell Metab., 27, 450, 10.1016/j.cmet.2017.11.003 · DOI
  53. Schiellerup, 2019, Gut hormones and their effect on bone metabolism. Potential drug therapies in future osteoporosis treatment, Front. Endocrinol. (Lausanne), 10, 75, 10.3389/fendo.2019.00075 · DOI

Cited by

See all 96

Metadata

Authors
El, K., & Campbell, J. E.
Venue
Peptides
Publisher
Elsevier BV
Published
2020-03
Volume
125
Pages
170213
ISSN
0196-9781 (ISSN-L)
OpenAlex
W2990930253
Cited by
96
References
29
FWCI
6.27
Type
journal article
Language
en
Open access
green
Licence
  • www.elsevier.com/tdm/userlicense/1.0/ (tdm)
  • www.elsevier.com/legal/tdmrep-license (tdm)
Funders
  • National Institute of Diabetes and Digestive and Kidney Diseases (T32 DK007012-41)
  • National Institutes of Health
  • American Diabetes Association (1-18-JDF-017)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The role of GIP in α-cells and glucagon secretion. https://app.cochat.ai/papers/10.1016/j.peptides.2019.170213
The paper
El, K., & Campbell, J. E. (2020). The role of GIP in α-cells and glucagon secretion. Peptides. https://doi.org/10.1016/j.peptides.2019.170213

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.